Study
|
Antioxidant group
|
Control group
|
---|
|
No. of patients (n)
|
No. of PEP (n)
|
PEP stratified by severity
|
No. of patients (n)
|
No. of PEP (n)
|
PEP stratified by severity
|
---|
| | |
Mild
|
Moderate
|
Severe
| | |
Mild
|
Moderate
|
Severe
|
---|
Wollschläger et al. [21]
|
20
|
2
|
NA
|
NA
|
NA
|
20
|
3
|
NA
|
NA
|
NA
|
Budzyńska et al. [22]
|
99
|
12
|
9
|
2
|
1
|
101
|
8
|
5
|
3
|
0
|
Lavy et al. [23]
|
141
|
14
|
10
|
4
|
0
|
180
|
17
|
9
|
4
|
4
|
Katsinelos et al. [24]
|
124
|
15
|
8
|
7
|
0
|
125
|
12
|
7
|
5
|
0
|
Katsinelos et al. [25]
|
125
|
4
|
4
|
0
|
0
|
118
|
21
|
8
|
11
|
2
|
Mosler et al. [26]
|
355
|
46
|
28
|
16
|
2
|
346
|
42
|
24
|
16
|
2
|
Milewski et al. [27]
|
55
|
4
|
NA
|
NA
|
NA
|
51
|
6
|
NA
|
NA
|
NA
|
Kapetanos et al. [28]
|
158
|
9
|
6
|
1
|
2
|
162
|
5
|
4
|
0
|
1
|
Romagnuolo et al. [29]
|
293
|
16
|
8
|
6
|
2
|
293
|
12
|
4
|
6
|
2
|
Martinez et al. [30]
|
85
|
2
|
NA
|
NA
|
NA
|
85
|
8
|
NA
|
NA
|
NA
|
Abbasinazari et al. [31]
|
29
|
3
|
2
|
1
|
0
|
45
|
5
|
3
|
2
|
0
|
- ERCP = endoscopic retrograde cholangiopancreatography, PEP = post-ERCP pancreatitis, NA = not available.